We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $982M
1-Year Est. Return 210.17%
This Fund
S&P 500
This Quarter Est. Return
+15.57%
1 Year Est. Return
+210.17%
3 Year Est. Return
+787.54%
5 Year Est. Return
+404.19%
10 Year Est. Return
–
AUM
$296M
AUM Growth
-$17M
Cap. Flow
-$53.5M
Cap. Flow %
-18.07%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$53.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
$159M 53.64%
19,963,157
– –
MRUS
2
DELISTED
Merus
MRUS
$44M 14.85%
1,600,000
– –
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$708M
$34.3M 11.59%
3,760,869
– –
NAMS icon
4
NewAmsterdam Pharma
NAMS
$3.25B
$32.1M 10.82%
2,869,565
– –
AURA icon
5
Aura Biosciences
AURA
$725M
$26.9M 9.09%
3,039,892
– –
PCVX icon
6
Vaxcyte
PCVX
$7.81B
– –
-1,049,893
Closed -$53.5M

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
FFS
Forge Financial Services Edmond, Oklahoma $987M AUM 14.12% 1-Year Est. Return
PCM
Polymer Capital Management New York $988M AUM 56.33% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Medicxi Ventures Management's Q4 2023 Portfolio in Review

As of Q4 2023, Medicxi Ventures Management held 6 positions worth $296M, down 5.4% from $313M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Medicxi Ventures Management withdrew a net $53.5M in Q4 2023, closing 1 position. Its most notable exit was Vaxcyte, an estimated $53.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Medicxi Ventures Management fully exited Vaxcyte in Q4 2023, selling an estimated $53.5M.
  • Medicxi Ventures Management's ten largest holdings make up 100% of its $296M portfolio in Q4 2023.
  • Medicxi Ventures Management opened 0 new positions and closed 1 in Q4 2023.
  • Medicxi Ventures Management's portfolio value fell 5.4% quarter-over-quarter to $296M.

Based on Medicxi Ventures Management's 13F filing for Q4 2023, filed 1 Feb 2024.